Virpax Pharma – New Drug Candidate – Nasal Spray to Prevent Spread of Respiratory Infections

Tony Mack, Chairman and CEO of Virpax Pharma, discusses a new drug candidate in the pipeline  that uses the Intranasal MET-nanoparticle dispersion delivery  technology, called AnQlar™,  a prophylactic, antiviral product candidate formulated to prevent the spread of respiratory infections like influenza, SARS-CoV-2, and rhinovirus. If clinical studies prove AnQlar is safe and effective, the company envisions the product to be used broadly, possibly as an OTC product, and by essential workers, high-risk individuals, and others entering close spaces. In addition, preclinical animal studies demonstrated no viral brain load in animal brain tissue, an important observation as recent studies have shown neurological conditions with survivors of COVID (Long-COVID). 

Anthony P. Mack is an entrepreneur who has founded three successful pharmaceutical companies, served on executive boards and has more than 35 years of experience in the industry as well as in finance. Prior to founding Virpax, Mr. Mack founded Scilex Pharmaceuticals and served as President, CEO and Director until February 2018. Scilex was sold to a publicly traded company. Mr. Mack founded his first pharmaceutical company, ProSolus Pharmaceuticals, in 2009 where he served as President and Director before selling the company to Mission Pharmacal in 2015. Mr. Mack has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances through high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. Prior to his pharmaceutical career, Mr. Mack worked in the financial sector, starting as a Series 7 broker dealer then a Series 24 licensed Principal, allowing him to supervise and manage brokers at affiliated branches. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.